USD
+$0.00
(+0.00%
)At Close (As of Dec 11, 2025)
$304.95M
Market Cap
0.469
P/E Ratio
5.16
EPS
$2.95
52 Week High
$0.30
52 Week Low
HEALTHCARE
Sector
| Field | Value (USD) |
|---|---|
| Gross Profit | $6.5M |
| Total Revenue | $9.8M |
| Cost Of Revenue | $3.3M |
| Costof Goods And Services Sold | $3.3M |
| Operating Income | -$5.8M |
| Selling General And Administrative | $7.4M |
| Research And Development | $42K |
| Operating Expenses | $12M |
| Investment Income Net | - |
| Net Interest Income | -$904K |
| Interest Income | $96K |
| Interest Expense | $904K |
| Non Interest Income | - |
| Other Non Operating Income | - |
| Depreciation | - |
| Depreciation And Amortization | $381K |
| Income Before Tax | -$7.2M |
| Income Tax Expense | - |
| Interest And Debt Expense | - |
| Net Income From Continuing Operations | -$7.2M |
| Comprehensive Income Net Of Tax | - |
| Ebit | -$6.3M |
| Ebitda | -$5.9M |
| Net Income | -$7.2M |
| Field | Value (USD) |
|---|---|
| Gross Profit | $6.5M |
| Total Revenue | $9.8M |
| Cost Of Revenue | $3.3M |
| Costof Goods And Services Sold | $3.3M |
| Operating Income | -$5.8M |
| Selling General And Administrative | $7.4M |
| Research And Development | $42K |
| Operating Expenses | $12M |
| Investment Income Net | - |
| Net Interest Income | -$904K |
| Interest Income | $96K |
| Interest Expense | $904K |
| Non Interest Income | - |
| Other Non Operating Income | - |
| Depreciation | - |
| Depreciation And Amortization | $381K |
| Income Before Tax | -$7.2M |
| Income Tax Expense | - |
| Interest And Debt Expense | - |
| Net Income From Continuing Operations | -$7.2M |
| Comprehensive Income Net Of Tax | - |
| Ebit | -$6.3M |
| Ebitda | -$5.9M |
| Net Income | -$7.2M |
| Field | Value |
|---|---|
| Ex Dividend Date | 2025-09-30 |
| Declaration Date | 2025-08-26 |
| Record Date | 2025-09-15 |
| Payment Date | 2025-09-29 |
| Amount | 0.8 |
Sector: HEALTHCARE
Industry: BIOTECHNOLOGY
NovaBay Pharmaceuticals Inc. (NBY) is a California-based innovator in the field of ocular health, dedicated to developing advanced medical devices and therapeutics aimed at treating eye infections and inflammation. Utilizing its proprietary technologies, the company addresses critical unmet clinical needs within the expanding eye care market. NovaBay is strategically positioned to enhance patient outcomes while offering a compelling investment opportunity for institutional investors looking to capitalize on advancements in healthcare and medical devices.